EE365 Cost-Minimization and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Compared With Acalabrutinib in the First Line and R/R Chronic Lymphocytic Leukemia From the Brazilian Private Healthcare Perspective
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.611
https://www.valueinhealthjournal.com/article/S1098-3015(22)02815-7/fulltext
Title :
EE365 Cost-Minimization and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Compared With Acalabrutinib in the First Line and R/R Chronic Lymphocytic Leukemia From the Brazilian Private Healthcare Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02815-7&doi=10.1016/j.jval.2022.09.611
First page :
Section Title :
Open access? :
No
Section Order :
10141